Skip to content
Company Analysis

Pacific Biosciences of Californ PACB

A comprehensive view of key metrics, scores, and financial health for Pacific Biosciences of Californ

Overview of Pacific Biosciences of California, Inc.

PACB NMS
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Small Cap
Pacific Biosciences of California, Inc. (PACB), is a Small Cap company, in the Medical Devices industry, last closed at $1.40, about 0.0% overvalued vs fair value, -6.0% 1Y return, ranked 648/1145 in sector.
Metrics Rev Growth 3.9% ROE -213.5% Gross Margin 28.6%
USD 1.40
2.94%
(Delayed)
• Vol 90d: 78.4%
52-Week Range
Market Cap
$500.07M
Enterprise Value
$1.15B
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 82%
Confidence: 84%
Updated: Jul 5
Top Beats

Quick Facts

Website https://www.pacb.com
HQ Menlo Park, CA
Employees 485
Fiscal year Dec 31

Next Events

Earnings Aug 6 Estimated

Fair Value Snapshot

Bear Base Bull
$-2
$-2
$-2
Current: $1.40

Engine Room Money Flow™

Small Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$160.0M
3.9%%
Gross Profit
$45.8M
22.8%%
Operating Income (GAAP)
$-557.6M
-91.8%%
EBITDA
$-152.7M
37.1%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
28.6%
Poor

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
0/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Pacific Biosciences of Californ's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
27
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
20
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 83% Coverage
Trade-Off Triangle Visualization A ternary plot showing PACB's balance between Growth (49.1%), Profitability (32.1%), and Safety (18.8%). Growth 49% Safety 19% Profitability 32%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

34th percentile vs peers
35
Key Signals
Rev Growth YoY 3.9% 42p Revenue CAGR 3Y 7.6% 52p EPS Growth YoY -69.5% 12p Asset Growth YoY -37.8% 5p
Strengths

No notable strengths identified for this axis.

Risks
  • EPS Growth YoY in bottom 20% of peers (-69.5%)

Profitability

22th percentile vs peers
23
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

13th percentile vs peers
13
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Pacific Biosciences of Californ.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-1.86
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000